Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.
in combination with LAZCLUZE ® (lazertinib) for first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions ...
EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...
Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective, according to new research published in Science ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...
Gliomas are devastating CNS malignancies characterized by extreme molecular heterogeneity and poor prognosis; the fibroblast growth factor receptor (FGFR) signaling axis, which drives proliferation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results